ArticleFrontiers in cardiovascular medicine2023
Safety of Lumason® (SonoVue®) in special populations and critically ill patients.
Article in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Type, severity, frequency and management of adverse reactions associated with ultrasound contrast agents: a systematic review and meta-analysis.European radiology · 2026Pooled it
- Hepatic Histotripsy after Contrast-Enhanced Ultrasound: Evaluation of Safety and Efficacy in an In Vivo Swine Model.Journal of vascular and interventional radiology : JVIR · 2026Article
- The Safety of Ultrasound Contrast Agents in Children.Diagnostics (Basel, Switzerland) · 2026Article
- Quantification of Kidney Inflammation Using Nanobubble-mediated Contrast Enhanced Ultrasound.Nanotheranostics · 2026Article
- Echo contrast medium: How the use of contrast echocardiography (ultrasound contrast agents) can improve patient care.World journal of methodology · 2025Review
- How to Perform Cardiac Contrast-Enhanced Ultrasound (cCEUS): Part II-Advanced Applications and Interpretation.Diagnostics (Basel, Switzerland) · 2025Review
- How to Perform Cardiac Contrast-Enhanced Ultrasound (cCEUS): Part I.Diagnostics (Basel, Switzerland) · 2025Review
- Super-Resolution Contrast-Enhanced Ultrasound Examination Down to the Microvasculature Enables Quantitative Analysis of Liver Lesions: First Results.Life (Basel, Switzerland) · 2025Article
- Analysing the Renal Vasculature Using Super-Resolution Ultrasound Imaging: Considerations for Clinical and Research Applications.Diagnostics (Basel, Switzerland) · 2025Article
- Contemporary Safety of Ultrasound Enhancing Agents in a Nationwide Analysis.Journal of the American Heart Association · 2025Article
- Low-intensity focused ultrasound combined with microbubbles for non-invasive downregulation of rabbit carotid body activity in the treatment of hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Comments and Illustrations of the European Federation of Societies for Ultrasound in Medicine (EFSUMB) Guidelines: Rare Malignant Pulmonal and Pleural Tumors: Primary Pulmonary Sarcoma and Mesothelioma, Imaging Features on Transthoracic Ultrasound.Diagnostics (Basel, Switzerland) · 2024Review
- The value of contrast-enhanced ultrasound in cervical cancer assessed in comparison with magnetic resonance imaging.Medicine and pharmacy reports · 2024Article
- Safety of the contrast enhancement agent sulfur hexafluoride in ultrasound: Analysis of the Federal Drug Administration Adverse Event Reporting System database.Endoscopic ultrasoundArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence for the safe use of Lumason® (SonoVue®), an ultrasound enhancing agent (UEA), in special patient populations is critical to enable healthcare professionals to make informed decisions concerning its use in such patients. Herein, we provide insight on the safety and tolerability of Lumason® in special patient populations. Findings are presented from clinical pharmacology studies conducted in patients with compromised cardiopulmonary conditions, from a retrospective study performed in critically ill patients, and from post-marketing surveillance data from over 20 years of market use of Lumason® (SonoVue®). No detrimental effects of Lumason® on cardiac electrophysiology were observed in patients with coronary artery disease (CAD), and no significant effects on pulmonary hemodynamics were noted in patients with pulmonary hypertension or congestive heart failure. Similarly, no effects on several assessments of pulmonary function (e.g., FVC) were observed in patients with chronic obstructive pulmonary disease (COPD), and no clinically meaningful changes in O
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.